Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

SMW started producing products for growing single crystals

2/16/23 MGNZ

Modernization of Cherepetskaya TPP can paid for by industry

2/16/23 IRAO

QuidelOrtho's revenue doubled in 2022

2/16/23 QDEL

Energy Transfer reported for 2022

2/16/23 ET

Aerojet Rocketdyne's 2022 profits halved

2/16/23 AJRD

Cisco reported six months of fiscal year 2023

2/16/23 CSCO

Noventiq shareholders approve change of jurisdiction from Cyprus to the Cayman Islands

2/16/23 SFTL

Segezha reported for 2022 according to RAS

2/16/23 SGZH

The Cisco Systems announced a quarterly dividend

2/15/23 CSCO

EL5-Energo unveiled a new company logo

2/15/23 ELFV